[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP4215533A4 - PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT - Google Patents

PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT Download PDF

Info

Publication number
EP4215533A4
EP4215533A4 EP21869716.7A EP21869716A EP4215533A4 EP 4215533 A4 EP4215533 A4 EP 4215533A4 EP 21869716 A EP21869716 A EP 21869716A EP 4215533 A4 EP4215533 A4 EP 4215533A4
Authority
EP
European Patent Office
Prior art keywords
pyrimidopyrimidinone
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21869716.7A
Other languages
German (de)
French (fr)
Other versions
EP4215533A1 (en
Inventor
Young Jun Park
Sung Jun Park
Hyebin YOO
Hyunnam SONG
Si-Eun YUN
Sojin Park
Joon Woo Kim
Sung Il Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axceso Biopharma Co Ltd
Original Assignee
Axceso Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axceso Biopharma Co Ltd filed Critical Axceso Biopharma Co Ltd
Publication of EP4215533A1 publication Critical patent/EP4215533A1/en
Publication of EP4215533A4 publication Critical patent/EP4215533A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP21869716.7A 2020-09-16 2021-09-15 PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT Pending EP4215533A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200119100 2020-09-16
PCT/KR2021/012616 WO2022060094A1 (en) 2020-09-16 2021-09-15 Pyrimidopyrimidinone compound and pharmaceutical composition comprising same

Publications (2)

Publication Number Publication Date
EP4215533A1 EP4215533A1 (en) 2023-07-26
EP4215533A4 true EP4215533A4 (en) 2024-12-18

Family

ID=80777269

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21869716.7A Pending EP4215533A4 (en) 2020-09-16 2021-09-15 PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT

Country Status (11)

Country Link
US (1) US20230348474A1 (en)
EP (1) EP4215533A4 (en)
JP (1) JP2023541052A (en)
KR (1) KR102673031B1 (en)
CN (1) CN116137815A (en)
AU (1) AU2021344164A1 (en)
BR (1) BR112023004179A2 (en)
CA (1) CA3190461A1 (en)
IL (1) IL300920A (en)
MX (1) MX2023003087A (en)
WO (1) WO2022060094A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006024486A2 (en) * 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
WO2018009544A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2019204609A1 (en) * 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159449A (en) 2005-12-13 2017-01-13 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
GB201315072D0 (en) * 2013-08-23 2013-10-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006024486A2 (en) * 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
WO2018009544A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2019204609A1 (en) * 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHO ET AL.: "First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia", J. MED. CHEM., vol. 61, no. 18, 27 September 2018 (2018-09-27), US, pages 8353 - 8373, XP055829016, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00882> DOI: 10.1021/acs.jmedchem.8b00882 *
See also references of WO2022060094A1 *

Also Published As

Publication number Publication date
US20230348474A1 (en) 2023-11-02
CA3190461A1 (en) 2022-03-24
KR102673031B1 (en) 2024-06-07
CN116137815A (en) 2023-05-19
EP4215533A1 (en) 2023-07-26
MX2023003087A (en) 2023-04-14
WO2022060094A1 (en) 2022-03-24
BR112023004179A2 (en) 2023-04-11
AU2021344164A9 (en) 2024-03-21
AU2021344164A1 (en) 2023-05-04
IL300920A (en) 2023-04-01
KR20220036895A (en) 2022-03-23
JP2023541052A (en) 2023-09-27

Similar Documents

Publication Publication Date Title
EP3647311C0 (en) RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD AND USE THEREOF
MA47816A (en) PHARMACEUTICAL COMPOSITION CONSISTING OF SELEXIPAG
EP3918062A4 (en) SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING THEM
EP3368555A4 (en) DOUBLE-FUNCTION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
MA51747A (en) LOW PH PHARMACEUTICAL ANTIBODY FORMULATION
EP3412660A4 (en) SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
EP3928607A4 (en) HETEROCYCLIC COMPOUND AND AGENT THEREOF FOR COMBATING HARMFUL ARTHROPODS
EP3474844A4 (en) PHARMACEUTICAL FORM FOR SPRAY AND SMOKE
EP4056558A4 (en) INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND ITS APPLICATIONS
EP4223759A4 (en) PYRAZOLOPYRIDAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE
EP3856242A4 (en) ANTI-SIGLEC ANTIBODIES, PHARMACEUTICAL COMPOSITION COMPRISING IT, AND THEIR USES
EP3542821A4 (en) MOLECULE INDUCING THE DEGRADATION OF p53 AND PHARMACEUTICAL COMPOSITION
EP3575291A4 (en) POLYFLUORO SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND APPLICATIONS THEREOF
EP3363803A4 (en) UREA-BASED PEEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, PREPARATION METHOD AND USES THEREOF
EP3324954A4 (en) AMINO-NAPTHOQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION BLOCKING THE UBIQUITIN-PROTEASE SYSTEM IN DISEASES
DK4110292T3 (en) Liquid pharmaceutical composition comprising ensifenthrin and glycopyrrolate
EP4082614A4 (en) ACYLSULFAMIDE COMPOUND AND ITS PHARMACEUTICAL USE
MA53507A (en) NEW HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
EP3773654A4 (en) PHARMACEUTICAL COMPOSITIONS OF THE ACTIVE SUBSTANCE AND RELATED PROCEDURES
EP3835311C0 (en) NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT
MA45158A (en) PHARMACEUTICAL COMPOSITION CONSISTING OF ÉTEPLIRSEN
EP3492461A4 (en) NITROGEN HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF
EP3434681A4 (en) CURCUMIN-BORON COMPLEX AND PHARMACEUTICAL AGENT CONTAINING THE SAME
EP3805210A4 (en) NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230413

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20241114

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101ALI20241108BHEP

Ipc: A61P 35/00 20060101ALI20241108BHEP

Ipc: C07D 487/04 20060101AFI20241108BHEP